Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01974349 · ClinicalTrials.gov registry record · Phase 1
To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers
A Phase 1 study of Solid Tumours, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT01974349: Completed Phase 1 study of Solid Tumours, sponsored by AstraZeneca.
NCT01974349 is a Phase 1 study of Solid Tumours that has completed, run by AstraZeneca. The registered enrollment target is 39 participants, below the 142-participant average among 9 other Solid Tumours trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01974349, a Phase 1 study of Solid Tumours, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
Study to assess the effect of food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers
Primary Outcome
Curve taken during each of the 2 treatments
Conditions Studied
Interventions
- DRUG selumetinib (oral)
Study Locations (1)
Kansas
- Research Site - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2013-11 |
| Est. Completion | 2014-02 |
| Phase | Phase 1 |
What the finished NCT01974349 record still lists
NCT01974349 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 142-participant average among 9 other Solid Tumours trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Solid Tumours appearing as the primary indexed condition, and to 1 intervention - of which selumetinib (oral) is the first listed.
NCT01974349 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT01974349 about?
NCT01974349 is a clinical study titled "To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers". Study to assess the effect of food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers
What is the current status of trial NCT01974349?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2013-11. Estimated completion is 2014-02.
What conditions does trial NCT01974349 study?
This clinical trial studies the following conditions: Solid Tumours.
What interventions are being tested in trial NCT01974349?
The interventions under investigation include: selumetinib (oral) (DRUG).
Who is sponsoring clinical trial NCT01974349?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01974349 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumours
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01974349's enrollment target sits among peer trials
39 9th of 9 higher than 1 of 9 other Solid Tumours trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumours trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it Helps
RECRUITING · Phase 1
-
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
RECRUITING · Phase 1
-
Ispinesib In Combination With Carboplatin In Patients With Solid Tumors
COMPLETED · Phase 1
-
To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers
COMPLETED · Phase 1
-
Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia